Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low – Here’s What Happened

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) reached a new 52-week low during trading on Friday . The company traded as low as $6.2175 and last traded at $10.76, with a volume of 58999 shares changing hands. The stock had previously closed at $7.7550.

Analyst Upgrades and Downgrades

TVGN has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $100.00.

Tevogen Bio Stock Performance

The business has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.53. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -42.16 and a beta of -0.76.

Institutional Trading of Tevogen Bio

Several hedge funds and other institutional investors have recently made changes to their positions in TVGN. Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.